Shionogi B.V.

Antibacterial and Gram-negative infection research

Shionogi B.V. Medical Sciences supports clinical research in aerobic Gram-negative bacterial infections, with attention to severe hospital-based presentations such as complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired pneumonia, ventilator-associated pneumonia, and bacteremia or sepsis. The work also includes pediatric infectious disease settings in very young infants.

  • Hospitalized pediatric infections
  • Complicated bacterial infections
  • Severe Gram-negative pathogens

Research activity in this area reflects a focus on treatment options for difficult-to-manage bacterial disease across inpatient and early-life populations.

Rare neuromuscular and metabolic disease

The sponsor is involved in clinical studies for late-onset Pompe disease, a lysosomal storage disorder associated with progressive muscle and respiratory impairment. This area of interest centers on supportive approaches alongside enzyme replacement therapy, with emphasis on lung function and disease burden in affected adults.

  • Late-onset Pompe disease
  • Respiratory muscle involvement
  • Enzyme replacement therapy

These studies place the sponsor within rare disease research that addresses chronic functional decline and multisystem involvement.

Respiratory viral infection research

Shionogi B.V. Medical Sciences also funds research in respiratory syncytial virus infection, including symptomatic disease in adults at elevated risk of progression to severe illness. The therapeutic interest is centered on antiviral treatment for community-managed respiratory infection and the prevention of worsening respiratory outcomes.

  • Respiratory syncytial virus
  • Symptomatic outpatient infection
  • High-risk adult respiratory disease

This area links the sponsor to clinical efforts in infectious disease and respiratory medicine.

Acute cerebrovascular disease

The sponsor’s portfolio includes studies in acute ischemic stroke, focusing on treatment approaches for adults with recent cerebral ischemic injury. This therapeutic domain falls within neurology and emergency care, where rapid intervention is central to limiting neurological damage and improving recovery potential.

  • Acute ischemic stroke
  • Cerebrovascular injury
  • Neurological recovery

Clinical research in this field reflects interest in acute stroke therapy and related vascular neurology care.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A Study of S-337395 for Adults Not in Hospital with Respiratory Syncytial Virus Who Are at High Risk of Severe Disease

    Recruiting

    2 1
    Investigated diseases:
    Bulgaria Poland
  • A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

    Recruiting

    2 1
    Belgium Denmark France Germany Italy The Netherlands +1
  • Study on Cefiderocol for Treating Gram-negative Bacterial Infections in Hospitalized Infants Under 3 Months

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Greece Spain
  • Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +3